TRK-3 Performance of Pachymetry

计划入组 30 人 · 首次发布于 2024 年 2 月 9 日

Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia

计划入组 33 人 · 首次发布于 2019 年 2 月 8 日

Drug-Drug Interaction Study of TRK-100STP

计划入组 24 人 · 首次发布于 2008 年 7 月 22 日

TRK-730

TRK-880

TRK-170

TRB CHEMEDICA

France

Ark Therapeutics Ltd.

United Kingdom

Trek Therapeutics PBC

United States

Next-Generation TRK Inhibitors Show Promise in Treating NTRK Fusion-Positive Cancers

Larotrectinib Shows High Efficacy in Pediatric Solid Tumors with NTRK Fusion

Vcare PharmaTech's Next-Generation TRK Inhibitor Eratrectinib Wins NMPA Approval for NTRK Fusion-Positive Solid Tumors